Compare Mercadolibre Inc (MELI) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Repligen Corporation Common Stock — how do they compare? Mercadolibre Inc trades at $1,825.09 (market cap $93.24B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Mercadolibre Inc is far larger — about 8.2× Repligen Corporation Common Stock's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Repligen Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mercadolibre Inc for 118 Days and Repligen Corporation Common Stock for 0 Days on average.
| MELI | RGEN | |
|---|---|---|
Market Cap | $93.24B | $11.31B |
Volume | 380,071 | 1,216,919 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.36K | $194.57 |
52-Week Low | $1.55K | $102.87 |
Typical Hold Time | 118 Days | 0 Days |
Enterprise Value | $100.88B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,876.04, down 0.87% on the day, with strong technical bullish signals from moving averages. The company demonstrates robust revenue growth, reaching $28.89 billion in 2025, though net income margin declined to 6.91%. Recent news highlights expansion in Brazil with one-hour delivery services and growing fintech credit portfolio, while analyst consensus remains strongly bullish with a $2,160 price target.
MELI presents a compelling growth story in Latin American e-commerce and fintech, supported by expanding market share and ecosystem integration. Key risks include macroeconomic pressures in Argentina and margin compression despite revenue growth. With 73% analyst buy ratings and institutional accumulation, the stock offers upside potential but requires monitoring of profitability trends and regional economic stability.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
